compani
usd pm et
summari larg produc brand-nam prescript drug offer wide rang treatment
neurolog disord diabet cancer condit
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
pm stock trade
sale grew yoy led continu robust
demand growth blockbust
diabet drug trulic sale
saw sale growth yoy taltz psoriasi
basaglar diabet saw
robust sale growth well
growth three drug none
expect face gener competit
sale drug humalog diabet
sale yoy lower
price ciali sale fell yoy
expect sharp declin ciali revenu
continu gener competit
approv expect take
consider market share brand
year think gener sale growth
around howev newer drug
like trulic taltz pick slack
along sever posit pipelin
show strong oper
perform sg slightli
versu contribut gain
adjust ep think see
oper margin improv
major capital-expenditure invest
neutral share think
headwind exclus loss key
drug strong demand growth newer
brand expect trulic basaglar
diabet taltz psoriai continu
lead way growth rate
yoy also expect meaning
sale contribut sever newli
breast cancer drug verzenio approv
fda likewis olumi
arthriti may drug continu
ramp alreadi gener
annual revenu roughli off-set
declin ciali think pipelin
continu backfil declin sale older
drug robust five applic
current regulatori review two
novel drug anoth phase trial
target
ep estim line histor
forward price-to-earnings averag risk view
unexpect patent challeng gener
lower-than-expect uptak new drug
regul drug price increas
risk assess reflect relentless effort
gener challeng compani brand-nam drug
intens competit brand drug maker
market share brand-nam indic
uncertainti relat drug develop regulatori
approv risk partial mitig divers
product portfolio drug gener
sale robust develop pipelin compani
typic drug phase later
stage regulatori approv approv pipelin
drug like fuel long-term sale growth even older
apr ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
vice-president financ
compani
corpor overview compani fifth largest drug maker term revenu
lead develop drug wide rang therapeut area includ cardiovascular
endocrinolog immunolog neurosci oncolog
drug portfolio drug portfolio concentr larger peer view
half revenu come top six drug compani top-sel drug includ trulic
diabet billion sale total humalog diabet billion sale
total alimta lung cancer billion sale total ciali erectil dysfunct
billion sale total forteo osteoporosi billion sale total
humulin diabet billion sale total
critic drug compani like consist success new drug growth mode order
off-set older drug declin sale due loss exclus competit new
improv treatment exampl type declin erectil dysfunct drug ciali whose
sale peak around billion declin patent expir convers
trulic diabet still earli exclus period expir achiev rapid sale
growth offset declin ciali sale
next five year face sever key exclus expir hope off-set growth
newer drug critic upcom patent expir end data exclus period includ forteo
sale alimta sale cymbalta sale given
larg expect sale impact alimta lung cancer upcom loss exclus
focus major acquisit dollar promis devlop asset oncolog detail major
develop section
research develop effort continu off-set declin sale older drug spend
heavili research develop keep new drug come pipelin
global drug market spend total billion repres total revenu
februari drug develop pipelin consist on-going clinic trial
variou phase total trial phase final stage human clinic trial
registr phase fda approv final regulatori review drug market phase
later trial new molecular entiti nme often greater market potenti
new indic trial intend expand treatment indic already-approv drug get
approv lung cancer drug approv new breast cancer indic
develop pipelin includ potenti new treatment wide rang condit includ
migrain diabet psoriasi pancreat cancer kidney diseas critic upcom pipelin event
includ potenti fda approv lasmiditan acut migrain galcanezumab cluster headach
potenti approv ramucirumab second-lin treatment hepatocellular cancer liver phase
data readout drug first-lin treatment lung cancer phase data readout
tanezumab sever pain indic
market profil world-wide total prescript drug sale project grow compound annual
growth rate compound-annual-growth-rate period accord forecast evaluatepharma
key driver growth age develop popul especi babi
boomer age prime year health care need emerg market like see materi faster
growth prescript sale develop market howev due view
emerg market demand pharmaceut spur rise standard live global middl
class expand gain access advanc health care
major develop septemb began process divest anim health
segment estim oper profit initi public offer sold
busi compani divest rest segment exchang offer
complet march june paid billion acquir phase cancer drug
pegilodecakin keep focu grow oncolog portfolio februari acquir
loxo oncolog approxim billion purchas bring pipelin highli select
potenti medicin patient genom defin cancer
financi trend sale increas billion billion repres
three-year compound annual growth rate compound-annual-growth-rate period adjust pre-tax
incom margin increas mainli due strong perform contain sg
cost remain roughli flat three-year period sale grew materi due
sale growth larg improv profit margin adjust pre-tax incom per share
grew three-year compound-annual-growth-rate compani conserv capit view
ebita-to-interest coverag around
redistribut reproduct prohibit without prior written permiss copyright cfra
compani
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
bullish sinc decemb technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
compani
outlook pharmaceut sub-industri
next year posit reflect
strong novel drug approv nda activ
food drug administr fda --
posit brand drug maker
repres lion share
improv gener profit margin
competit appear moder
overal posit view somewhat temper
expect lower growth overal
expect strong pace nda continu
next year aid continu robust
growth invest led major brand drug
compani banner year nda
fda new drug approv
repres surg approv compar
mani
new drug littl competit
provid tailwind brand drug
maker strong growth spend
primari driver novel approv uptick
industri increas
estim pace anoth year
growth septemb
growth mark rapid acceler
averag annual growth
side sub-industri
outlook earn growth gener
maker posit closer neutral fda
gener approv total
mani
compet version gener enter
sever gener
price deflat becam norm profit margin
contract surprisingli number
firm announc asset divestitur exit
 gener industri
bright side think lower competit
start impact note gener
approv tick vs
first materi declin least six
year also note move
averag gener applic lead
think anoth sign
mitig competit allow
moder gener deflat
modest improv gener profit margin
year ahead
anoth boost gener maker
record year fda first-gener approv
experienc
first-gener typic enter
market materi lower price
brand-nam counterpart allow
quick market share gain accordingli
major increas first-gener provid
revenu tailwind gener maker next
mitig posit outlook
sub-industri expect slower
prescript volum growth next
year strong gain health-insur
popul driven solid employ
growth view
think gain harder come
 approach full employ
remov tailwind prescript
volum growth assum
slower growth health plan roll gener
mean slower growth prescript volum
versu rise composit
drop
year date januari pharma
slip gain
base index
five-year market price perform
note sector sub-industri inform base
past perform indic futur perform
reli upon
compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
compani
keep target ep
estim tax reform benefit ep vs
ahead estim sale rose pharmaceut sale
driven strong sale new drug trulic taltz jardianc top sell
drug humalog ciali fell respect humalog sale
impact lower price due discount rebat also concern
declin anim health lower volum market access
headwind competit pressur posilac optiplex /jeffrey loo cfa
et cfra keep hold opinion share eli lilli
compani rais target peer
forward ep estim faster growth ep
vs in-lin estim rais ep
estim sale rose driven new
drug trulic taltz world-wide diabet sale rose
explor potenti spin-off sale expect
provid updat elanco sale
second largest anim health compani view potenti move posit
analyst research note compani news
et cfra keep hold opinion share compani
lift target
ep estim -- roughli line histor forward price-to-earnings averag
ep vs line consensu lower ep
estim start sale yoy
driven growth volum partial off-set decreas price
neg currenc impact growth led diabet drug trulic
yoy basaglar yoy well psoriasi drug
taltz yoy robust demand growth three drug
account total sale year ago total revenu growth
hinder loss exclus ciali revenu howev
face new gener competit saw annual sale declin
expect gener revenu growth around rapid
growth success newer drug balanc declin older one without
compani rais target
ep estim line histor averag forward price-to-earnings ep
vs consensu rais ep estim
sale yoy higher
volum partial off-set lower averag price growth led
diabet drug trulic yoy psoriasi drug taltz
yoy robust demand also improv margin
quarter cog sg grow slower revenu
combin effect strong sale growth cost contain estim
yoy increas adj pre-tax incom pipelin encourag fda
approv emgal migrain treatment think
competit sever new migrain drug approv year june
acquisit phase pegilodecakin think promis orphan
drug pancreat cancer /colin scarola
et cfra keep hold opinion share eli li
rais target in-lin peer
forward ep estim adjust ep vs
ahead estim aid lower-than-expect oper
cost due cost reduct effort improv product rais
ep estim ep estim
sale rose pharmaceut sale driven new product
trulic taltz cyramza basaglar also encourag
pipelin advanc phase trial tanezumab treat
osteoarthr met three co-primari endpoint empagliflozin treat
diabet also met primari endpoint announc spin
elanco anim health unit ipo say maxim
after-tax valu sharehold view spin-off posit
anim health unit struggl past year soft sale /jeffrey
et cfra keep hold opinion share eli lilli
compani keep target price line
peer ep estim rais
ep estim ep vs
ahead estim sale aid fx benefit rose driven
increas demand new drug trulic talz
basaglar oper cost fell drive oper
margin bp diabet volum growth rose note continu
soft anim health expect growth unit
separ fda advisori panel recommend approv baricitinib treat
moderate-to-sever rheumatoid arthriti dosag
approv dosag safeti concern particularli pulmonari
embol deep vein thrombosi note dose approv
europ expect work fda dose believ
dose key gain market share /jeffrey loo cfa
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
compani
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
compani
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
compani
